Target engagement
PPI PathFinder offers precise target engagement analysis by meticulously quantifying
how drug compounds influence protein-protein interactions (PPIs) in patient clinical samples.
By tracking PPI changes in response to various drug treatments, PPI PathFinder offers valuable insights into drug mechanisms.
This makes it an essential tool for PPI biomarker research and clinical trial support.
Analyzing how effectively a drug binds to its intended target allows a drug developer to assess its therapeutic potential.
PPI PathFinder is a robust analytical solution that provides comprehensive metrics in analysis of drug-target engagement
at the protein-protein interaction level in clinical samples, making it ideal for efficacy studies of targeted therapies.
Optimal dose selection
PROTEINA can provide guidelines for the optimal dose of a drug in development
Determining the right dosage ensures that the drug effectively targets cancer cells,
enhancing its therapeutic impact and lowering potential side effects.
Drug response prediction
Secure validated biomarkers for both single and combined drug therapies.
New biological insights can be secured through extensive analysis of a protein and its potential interactions.
By securing data from a treatment therapy that applies either a single or combined administration of drugs,
the mechanism of action of a drug can effectively be understood.
PPI PathFinder Dx
PPI PathFinder Dx explores each patient's unique protein-protein interaction (PPI) network patterns, providing healthcare
providers with advanced precision molecular diagnostics. Our innovative approach enables tailored treatment strategies,
ensuring more accurate and effective medical interventions for improved patient outcomes.
PPI PathFinder BCL2 Dx is dedicated to examining patients' drug dependencies, with a particular focus on the selective
PPI biomarkers that serve as significant parameters to predict efficacies of Venetoclax, a BCL-2 inhibitor.
| PPI PathFinder BCL2 Dx |
Targeted
PPI Biomarker |
Probe Binging Assay
(PBA) |
Complex
(CPX) |
Level
(Lv) |
| BCL2-BIM |
BCL2-BAX |
BCL2 |
| BCLxL-BIM |
BCLxL-BAK |
MCL1 |
| MCL1-BIM |
MCL1-BAK |
|
-
Quantification
Vital PPI biomarkers associated with
BCL2 inhibitor response are quantified
-
Analysis
PROTEINA Pi-Insight software converts
proteomic bioinformation into actionable data
-
Decision
User decides course of treatment action
using a clear "Go/No-Go" Indicator
The Drug Response Score (DRS) is meticulously scaled based on measurements of key PPI biomarkers from patient clinical samples,
helping physicians to offer tailored clinical insights and more personalized treatment plans for their patients.
Brochure
